DFS
Figure 3 · Panel A
Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Esther Natalie Oliva, Maria Cuzzola, Matteo Della Porta, Anna Candoni, Prassede Salutari, Giuseppe A Palumbo, Gianluigi Reda, Giuseppe Iannì, Matteo Zampini, Saverio D'Amico, Giovanni Tripepi, Debora Capelli, Caterina Alati, Maria Concetta Cannatà, Pasquale Niscola, Bianca Serio, Santina Barillà, Pellegrino Musto, Ernesto Vigna, Lorella Maria Antonia Melillo, Rocco Tripepi, Maria Elena Zannier, Yasuhito Nannya, Seishi Ogawa, Corrado Mammì
Int J Mol Sci 25(21) 11646
The achievement of complete remission (CR) is crucial for acute myeloid leukemia (AML) patients undertaking curative therapy, but relapse often occurs within months, highlighting the need for strategies to prolong disease-free survival (DFS). Our phase III study compared the efficacy and safety of azacitidine (AZA) to best supportive care (BSC) in elderly AML patients who achieved CR following intensive induction and consolidation therapy. This ancillary study (QOL-ONE Trans-2) evaluated biological changes in bone marrow using Next-Generation Sequencing (NGS). We analyzed baseline, randomization, and 6-month post-remission samples from 24 patients (median age of 71 and 12 males). High-throughput NGS targeted 350 myeloid malignancy-related genes, considering variants with a variant allele frequency ≥ 4%. At diagnosis, all patients had 5 to 17 (median = 10) mutations, with DNMT3A (42%), NPM1 (33%), and TET2 (33%) being most frequent. FANCA mutations in four patients were linked to a higher relapse risk (HR = 4.96, p = 0.02) for DFS at both 2 and 5 years. Further HLA-specific NGS analyses are ongoing to confirm these results and their therapeutic implications.
1 个 Figure · 2 个 KM 面板
Figure 3 Disease free survival up to 5 years in all randomized patients ( A ) and those stratified by unmutated (N = 20) and mutated (N = 4) FANCA genes ( B ) at diagnosis. DFS = disease-free survival.
这些图片未产生 KM 曲线结果,不在主页面重复展示。